Ignet
v2.0 Sign In

Gene Information

Gene symbol: HGF

Gene name: hepatocyte growth factor (hepapoietin A; scatter factor)

HGNC ID: 4893

Synonyms: SF, F-TCF, HGFB, HPTA

Related Genes

# Gene Symbol Number of hits
1 BCL2L1 1 hits
2 FAS 1 hits
3 FASLG 1 hits
4 IGF1 1 hits
5 INS 1 hits
6 MAP2K1 1 hits
7 RPL10 1 hits
8 WT1 1 hits

Related Sentences

# PMID Sentence
1 10456263 In addition, study of the Wilms' tumor suppressor, WT1, is revealing much about the pathogenesis of Wilms' tumor, urogenital development, and glomerular podocyte biology. c-met, the gene encoding the hepatocyte growth factor receptor, has recently been identified as a causative gene for hereditary papillary renal cancer.
2 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
3 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
4 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
5 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
6 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
7 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
8 11141501 Hepatocyte growth factor, but not insulin-like growth factor I, protects podocytes against cyclosporin A-induced apoptosis.
9 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
10 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
11 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
12 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
13 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
14 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
15 11141501 Cyclosporin A (CsA) nephropathy is associated with altered expression of apoptosis regulatory genes such as Fas-ligand and Bcl-2 family members in the glomerular, tubulointerstitial, and vascular compartments.
16 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
17 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
18 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
19 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
20 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
21 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
22 11141501 Both hepatocyte growth factor (HGF) and insulin-like growth factor (IGF-I) protect against apoptosis, and HGF specifically up-regulates Bcl-xL, a protein that regulates apoptosis.
23 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
24 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
25 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
26 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
27 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
28 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
29 11141501 We investigated whether Bcl-xL and Fas/Fas-ligand were regulated by CsA in cultured podocytes and whether CsA-induced apoptosis was prevented by HGF or IGF-I.
30 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
31 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
32 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
33 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
34 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
35 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
36 11141501 A murine podocyte cell line was treated with CsA in the presence or absence of HGF or IGF-I.
37 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
38 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
39 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
40 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
41 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
42 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
43 11141501 Apoptosis was quantitated by ELISA and by flow cytometry; Bcl-xL, Fas, and Fas-ligand were measured by Western blotting.
44 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
45 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
46 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
47 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
48 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
49 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
50 11141501 Inhibitors of MAP kinase/ERK kinase (MEK)-1 and of phosphatidylinositol 3'-kinase (PI3'-K) were used to determine the signaling pathways involved in Bcl-xL regulation.
51 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
52 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
53 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
54 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
55 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
56 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
57 11141501 HGF, but not IGF-I, prevented apoptosis and restored Bcl-xL levels.
58 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
59 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
60 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
61 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
62 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
63 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
64 11141501 The regulation of Bcl-xL by HGF was mediated by the PI3'-K but not by the MEK-1 pathway.
65 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
66 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
67 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
68 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
69 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
70 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.
71 11141501 Apoptosis was prevented by pretreatment with HGF but not IGF-I.